Cutter & CO Brokerage Inc. raised its stake in Mylan N.V. (NASDAQ:MYL) by 198.8% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 18,080 shares of the company’s stock after buying an additional 12,030 shares during the period. Cutter & CO Brokerage Inc.’s holdings in Mylan N.V. were worth $705,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. First Personal Financial Services boosted its stake in Mylan N.V. by 33.2% in the first quarter. First Personal Financial Services now owns 2,733 shares of the company’s stock valued at $107,000 after buying an additional 681 shares during the period. Kernodle & Katon Asset Management Group LLC boosted its stake in Mylan N.V. by 4.7% in the third quarter. Kernodle & Katon Asset Management Group LLC now owns 2,884 shares of the company’s stock valued at $110,000 after buying an additional 129 shares during the period. Ropes Wealth Advisors LLC purchased a new position in shares of Mylan N.V. during the first quarter worth $136,000. Mosaic Family Wealth LLC boosted its position in shares of Mylan N.V. by 12.5% in the third quarter. Mosaic Family Wealth LLC now owns 3,600 shares of the company’s stock worth $137,000 after buying an additional 400 shares during the last quarter. Finally, Oakworth Capital Inc. boosted its position in shares of Mylan N.V. by 30.7% in the first quarter. Oakworth Capital Inc. now owns 4,255 shares of the company’s stock worth $166,000 after buying an additional 1,000 shares during the last quarter. Institutional investors and hedge funds own 69.95% of the company’s stock.
Shares of Mylan N.V. (NASDAQ:MYL) traded down 0.70% during trading on Friday, reaching $36.72. The company’s stock had a trading volume of 8,784,868 shares. The stock has a market capitalization of $19.68 billion, a price-to-earnings ratio of 36.68 and a beta of 1.23. Mylan N.V. has a 1-year low of $33.60 and a 1-year high of $50.40. The company’s 50-day moving average price is $38.54 and its 200 day moving average price is $38.99.
Mylan N.V. (NASDAQ:MYL) last announced its quarterly earnings data on Wednesday, May 10th. The company reported $0.93 EPS for the quarter, beating the Zacks’ consensus estimate of $0.92 by $0.01. Mylan N.V. had a net margin of 4.59% and a return on equity of 23.69%. The business had revenue of $2.72 billion during the quarter, compared to analyst estimates of $2.81 billion. During the same quarter in the prior year, the business earned $0.76 earnings per share. The firm’s revenue for the quarter was up 24.1% on a year-over-year basis. Analysts anticipate that Mylan N.V. will post $5.19 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.themarketsdaily.com/2017/06/16/mylan-myl-stake-boosted-by-cutter-co-brokerage-inc-updated-updated.html.
MYL has been the topic of a number of research analyst reports. Royal Bank of Canada reduced their target price on Mylan N.V. from $39.00 to $36.00 and set a “sector perform” rating on the stock in a report on Thursday, May 11th. Mizuho lifted their target price on Mylan N.V. from $47.00 to $53.00 and gave the company a “buy” rating in a report on Monday, March 13th. ValuEngine cut Mylan N.V. from a “buy” rating to a “hold” rating in a report on Wednesday. Wells Fargo & Company reiterated a “market perform” rating and issued a $40.00 target price on shares of Mylan N.V. in a report on Wednesday, May 31st. Finally, Barclays PLC upgraded Mylan N.V. from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $47.00 to $50.00 in a research note on Monday, May 22nd. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $50.77.
In related news, President Rajiv Malik sold 25,000 shares of the stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $40.00, for a total value of $1,000,000.00. Following the completion of the transaction, the president now owns 799,855 shares of the company’s stock, valued at $31,994,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Laboratories Abbott sold 44,000,000 shares of the stock in a transaction dated Thursday, March 23rd. The stock was sold at an average price of $41.60, for a total transaction of $1,830,400,000.00. The disclosure for this sale can be found here. Insiders sold 44,035,000 shares of company stock valued at $1,831,800,000 in the last three months. Company insiders own 0.69% of the company’s stock.
About Mylan N.V.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.